CRISPR

CRISPR1-gria4a

ID
ZDB-CRISPR-220901-1
Name
CRISPR1-gria4a
Previous Names
None
Target
Sequence
5' - TGAGAGGTTCATGCACGGCG - 3'
ZFIN BLAST NCBI BLAST Ensembl UCSC BLAT
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
uva43 gria4a
Expression
Gene expression in Wild Types + CRISPR1-gria4a
No data available
Phenotype
Phenotype resulting from CRISPR1-gria4a
No data available
Phenotype of all Fish created by or utilizing CRISPR1-gria4a
Phenotype Fish Conditions Figures
spinal cord dorso-lateral region gria4a expression decreased amount, abnormal gria4auva43/uva43 standard conditions Fig. 1 from Piller et al., 2021
whole organism gria2b expression increased amount, abnormal gria4auva43/uva43 standard conditions Fig. 1 from Piller et al., 2021
whole organism gria4b expression increased amount, abnormal gria4auva43/uva43 standard conditions Fig. 1 from Piller et al., 2021
spinal cord glial cell migration decreased process quality, abnormal gria4auva43/uva43 standard conditions Fig. 5 from Piller et al., 2021
spinal cord dorsal region has fewer parts of type glioblast (sensu Vertebrata), abnormal gria4auva43/uva43 standard conditions Fig. 5 from Piller et al., 2021
whole organism gria4a expression decreased amount, abnormal gria4auva43/uva43 standard conditions Fig. 1 from Piller et al., 2021
spinal cord dorsal region has extra parts of type glioblast (sensu Vertebrata), abnormal gria4auva43/+ standard conditions Fig. 5 from Piller et al., 2021
whole organism gria2b expression increased amount, abnormal gria4auva43/+ standard conditions Fig. 1 from Piller et al., 2021
whole organism gria4b expression increased amount, abnormal gria4auva43/+ standard conditions Fig. 1 from Piller et al., 2021
spinal cord central nervous system myelination decreased process quality, abnormal gria4auva43/+; ue2Tg chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 7 from Piller et al., 2021
spinal cord central nervous system myelination decreased process quality, abnormal gria4auva43/+; ue2Tg standard conditions Fig. 7 from Piller et al., 2021
spinal cord glial cell migration process quality, ameliorated gria4auva43/+; uva56Tg; vu19Tg chemical treatment by environment: L-glutamate(1-) Fig. 4 from Piller et al., 2021
spinal cord central nervous system myelination process quality, ameliorated gria4auva43/uva43; ue2Tg chemical treatment by environment: Bay-K-8644 Fig. 10 from Piller et al., 2021
spinal cord central nervous system myelination decreased process quality, abnormal gria4auva43/uva43; ue2Tg control Fig. 7,  Fig. 8,  Fig. 10 from Piller et al., 2021
spinal cord central nervous system myelination decreased process quality, exacerbated gria4auva43/uva43; ue2Tg chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 7 from Piller et al., 2021
spinal cord glial cell migration decreased process quality, abnormal gria4auva43/uva43; ue2Tg; vu19Tg standard conditions Fig. 2,  Fig. 9 from Piller et al., 2021
spinal cord dorsal region has number of glioblast (sensu Vertebrata), ameliorated gria4auva43/uva43; ue2Tg; vu19Tg chemical treatment by environment: Bay-K-8644 Fig. 9 from Piller et al., 2021
spinal cord dorsal region has fewer parts of type glioblast (sensu Vertebrata), abnormal gria4auva43/uva43; ue2Tg; vu19Tg standard conditions Fig. 2,  Fig. 9 from Piller et al., 2021
spinal cord glial cell migration process quality, ameliorated gria4auva43/uva43; ue2Tg; vu19Tg chemical treatment by environment: Bay-K-8644 Fig. 9 from Piller et al., 2021
spinal cord glial cell migration process quality, ameliorated gria4auva43/uva43; uva56Tg; vu19Tg chemical treatment by environment: L-glutamate(1-) Fig. 4 from Piller et al., 2021
glioblast (sensu Vertebrata) cellular response to L-glutamate decreased process quality, abnormal gria4auva43/uva43; uva56Tg; vu19Tg control Fig. 4 from Piller et al., 2021
spinal cord glial cell migration process quality, ameliorated gria4auva43/uva43; vu17Tg; vu19Tg chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021
spinal cord glial cell migration decreased process quality, abnormal gria4auva43/uva43; vu17Tg; vu19Tg control Fig. 3 from Piller et al., 2021
spinal cord dorsal region has fewer parts of type glioblast (sensu Vertebrata), abnormal gria4auva43/uva43; vu17Tg; vu19Tg control Fig. 3 from Piller et al., 2021
spinal cord dorsal region has number of glioblast (sensu Vertebrata), ameliorated gria4auva43/uva43; vu17Tg; vu19Tg chemical treatment by environment: 2,3-Dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline Fig. 3 from Piller et al., 2021
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.